박지은 교수 연구실
article|
hybrid
·인용수 1
·2025
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
So Yeon Jeon, Min Soo Byun, Hye Ji Choi, Y. Kim, Chung Hee Gwag, Y. J. Oh, Jee Eun Park, Dahyun Yi, Gijung Jung, Hyejin Ahn, Bo Kyung Sohn, Joon Hyung Jung, Yoon Young Chang, Nayeong Kong, Hongyoon Choi, Keon Wook Kang, Chul‐Ho Sohn, Dong Young Lee
IF 11.1Alzheimer s & Dementia
초록
About a fourth of A+ patients in Korea met AUR criteria for anti-amyloid therapy. Donanemab eligibility slightly exceeded lecanemab despite narrower age criteria. MMSE z-score adjustment increased eligibility in older, less-educated individuals. Over 30% of eligible patients were excluded due to ARIA-related MRI findings. Culturally adapted cognitive thresholds are essential for equitable treatment access.
키워드
Appropriate Use CriteriaAge appropriateCognitionCulturally appropriateMEDLINE